-
80,000+
Men with prostate cancer
could ultimately benefit from CCS1477 annually
-
20,000+
Patients with blood cancers
multiple myeloma, AML, lymphomas
-
50+
Epigenetic-related targets
investigated over time by the CellCentric team
-
1
Drug prioritised, advanced
CCS1477 in the clinic, for multiple indications
The science
CCS1477, a first-in-class small molecule drug to treat prostate and other cancers
There is a large and growing population of prostate cancer patients that are resistant to second generation anti-hormonal drugs (Xtandi, Zytiga, Erleada). CCS1477 addresses this through targeting the key drivers of resistance and late stage disease; the androgen receptor (AR), AR splice variants (AR-SV) and c-Myc.
Other cancer tumours are also susceptible to p300/CBP inhibition, notably specific haematological cancers; multiple myeloma, acute myeloid leukaemia (AML) and certain lymphomas.
Backed by strong pre-clinical data, CCS1477 is now being trialed in patients.
A core team with deep experience of drug discovery and development
The company is supported by a strong network of clinical, scientific and commercial advisors. CellCentric also actively collaborates with a number of world-leading cancer research centres on the effects of CCS1477 and p300/CBP inhibition.